$17.61
+0.22 (+1.27%)
REPL News4 articles
FDA Panel Nod Sparks $763M Value Shift Between Melanoma Drugmakers
Replimune (REPL) soared 107% after an FDA panel endorsed RP1, while Iovance (IOVA) tumbled 13%, shifting $763 million in market value between the two melanoma therapy rivals.
Replimune Surges 107% as FDA Panel Backs RP1 Despite Data Discrepancies
Replimune shares soared 107% after an FDA panel endorsed RP1's efficacy data, despite conflicting response rates. The FDA decision is expected by August 2.
Replimune Rockets 131% on FDA Panel Backing for RP1
Replimune shares jumped 131% to $12.50 after an FDA panel voted 10-3 that RP1's efficacy data is interpretable and clinically important, adding nearly $600 million in market value.
Replimune Surges 85% on FDA Priority Review for Melanoma Drug
Replimune shares soared 85% after the FDA agreed to a priority review for its melanoma drug RP1, following a previous rejection. New trial data is expected soon.